Table 2.
Baseline demographic and disease characteristics (overall population)
| Characteristica | PBO (n = 646) |
CANA 100 mg (n = 833) |
CANA 300 mg (n = 834) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 334 (52) | 408 (49) | 404 (48) |
| Female | 312 (48) | 425 (51) | 430 (52) |
| Age, years | 56.3 (9.8) | 55.9 (10.1) | 55.7 (9.5) |
| Race, n (%) | |||
| White | 470 (73) | 591 (71) | 610 (73) |
| Black or African American | 28 (4) | 43 (5) | 48 (6) |
| Asian | 82 (13) | 103 (12) | 100 (12) |
| Otherb | 66 (10) | 96 (12) | 76 (9) |
| HbA1c, % | 8.0 (0.9) | 8.0 (0.9) | 8.0 (1.0) |
| Body weight, kg | 89.3 (21.7) | 89.8 (22.3) | 88.5 (22.0) |
| Systolic BP, mmHg | 128.2 (13.3) | 128.0 (12.8) | 128.8 (12.8) |
| eGFR, mL/min/1.73 m2 | 87.0 (19.8) | 88.3 (19.0) | 88.8 (18.9) |
| Duration of T2DM, years | 7.5 (6.2) | 7.2 (5.8) | 7.4 (6.2) |
Data have been previously reported [19, 22, 24]
PBO placebo, CANA canagliflozin, BP blood pressure, eGFR estimated glomerular filtration rate, T2DM type 2 diabetes mellitus, SD standard deviation
aData are mean (SD) unless otherwise indicated
bIncludes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported